Member Info for gixer

By-Health: Investor Relations Activity

Q: Progress of Qingluosu and pricing principles of Natural Doctor products.

A: Qingluosu is currently in the material supplementation stage. Natural Doctor is positioned as a high-end brand. Its DHA products use raw materials exclusively supplied by DSM, and the suggested retail price matches its

brand positioning

https://data.eastmoney.com/notices/detail/300146/AN202604121821139097.html

Https://finance.sina.com.cn/stock/relnews/cn/2026-04-08/doc-inhtuqfx9567622.shtml

You can check this site to see when the next batch gets tested.

https://choice.wetestyoutrust.com/supplement-search/optimum-nutrition/platinum-pump-pre-workout

Why are we seeing a delayed trade from the 2nd of April just showing up?

Insert puzzled face emoji.

To be honest I have not had a chance to read the whole thing yet but there appears to be no indication as to who funded this publication.

Asim K. Duttaroy - University of Oslo

Ruedi Duss - DSM-Firmenich

with Chettinad Academy of Research and Education and Chettinad Hospital and Research Institute in India being involved.

"Authors contribution

Asim K. Duttaroy wrote the original draft of the manuscript. Surajit

Pathak wrote and edited the manuscript. Ruedi Duss critically reviewed

the manuscript. Asim K. Duttaroy, Surajit Pathak, Ruedi Duss, Amit Dey,

and Keerthi N. conducted the wide-ranging aspects of manuscript

preparation and pictorial representations. Antara Banerjee, Surajit

Pathak, Asim K. Duttaroy, and Ruedi Duss critically reviewed and

revised the manuscript and provided feedback. All authors read and

approved the final manuscript."

If I was to guess, possibly DSM ???????

Volume 140, May 2026

"An up-to-date review on water-soluble tomato concentrate (Fruitflow®) and healthy ageing: roles of its bioactive compounds and mechanism of action"

https://www.sciencedirect.com/science/article/pii/S1756464626001337

Just to add.

The company has said "it may need to raise funds" so maybe aye and maybe nae.

I don't know who assured you but if the company had said "no more dilution" then IMO the share price would be far higher than 1p.

Better buying this afternoon

https://postimg.cc/WD6g0nVz

Https://www.netralnews.com/ekstrak-tomat-dinilai-efektif-cegah-pembekuan-darah-setara-aspirin/UTVINmhLMjk3VVk0cnBxejFGZUtpUT09

"Tomato Extract Deemed as Effective at Preventing Blood Clots as Aspirin"

Https://postimg.cc/N2MdsMHZ

"Only 50 items were added to your cart due to availability"

Still available on their own website.

https://nroute.co.in/products/heartisafe

I would say, unlikely.

Https://baijiahao.baidu.com/s?id=1860970722298452123&wfr=spider&for=pc

Everhopeful, I posted on the 16th that Stuart Lucas & Family had increased their holding by 6.2 million.

Hope you are right Willy but I am not sure SAMR announce Blue Cap approvals in batches and we are still waiting on the health claim.

Hopefully very soon.

And a 2,380,000 and 2,500,000 from yesterday

Here is an article from 2021 that states

"As a result, we can see that newly emerging food ingredients with significant innovation and the ability to generate super-premium prices, such as FruitFlow tomato juice powder (6000 RMB/kg), tomato powder with high hexahydro- and octahydrolycopene content (8000 RMB/kg), black pepper extract (piperine) with enhanced efficacy, and the recently very popular NMN, are all introduced by foreign companies."

https://baijiahao.baidu.com/s?id=1693898004131476920&wfr=spider&for=pc

So about £650 @ 6000 RMB / kg

Any evidence we have had in the past would suggest these quoted figures per kg are wrong.

Make of this what you think.....

I can't find anything else on it atm but seems to talk about a project to compare Fruitflow with Asprin.

Taken from Chinese chat board.

Global: DSM, By-Health, and other companies specializing in cardiovascular health dietary supplements.

5. Comparison with Aspirin (Understand at a glance)

sheet

Project: Fruitflow (Aspirin)

Source: Tomato extract (natural); Chemical synthesis (pharmaceutical)

Its functions include regulating abnormal aggregation, maintaining normal coagulation, strongly inhibiting aggregation, and reducing the risk of bleeding.

Mild side effects include gastrointestinal discomfort, gastric mucosal damage, and risk of bleeding.

Positioning: Dietary supplements (daily maintenance) Medication (treatment/prevention)

Suitable for daily vascular maintenance and prevention of cardiovascular diseases in middle-aged and elderly people under medical advice.

6. Market and Products

- Domestic mainstay: By-Health New Luosu Tablets (with Qingluosu as the core ingredient)

- Price: Raw materials approximately 1000–1500 RMB/kg; finished product approximately 200–300 RMB per bottle (30–60 tablets)

- Trend: Naturalizing cardiovascular health, with a CAGR of approximately 25% from 2025 to 2030.

https://caifuhao.eastmoney.com/news/20260317102800422914060